Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.70 |
| ▸ | AGPAT2 | O15120 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520484 | 0.92 | PTGES (0.72) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL4510506 | 0.84 | PTGES (0.74) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL4506643 | 0.84 | PTGES (0.83) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL4518282 | 0.82 | PTGES (1.00) | PTGESAGPAT2MAPTTP53 | |
| SCHEMBL4498498 | 0.81 | PTGES (0.81) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL6124596 | 0.73 | CYP2C9 (0.67) | PTGESAGPAT2MAPTTHRB | |
| SCHEMBL4514083 | 0.73 | MAPT (0.73) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL4522223 | 0.72 | PTGES (0.82) | PTGESAGPAT2MAPTTHRBTP53 | |
| SCHEMBL4516675 | 0.71 | PTGES (0.87) | PTGESAGPAT2MAPTTP53SMN1; SMN2 | |
| SCHEMBL10590299 | 0.71 | AGPAT2 (0.50) | AGPAT2MAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | PTGES 162/4885AGPAT2 4533/4885MAPT 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.